SCHEMBL3185199

SCHEMBL3185199

COC(=O)/C=C/c1ccc2c(c1)CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.64
NR1H2 P55055 2/20 0.61
ESR2 Q92731 1/20 0.56
MAPT P10636 4/20 0.45
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
BCHE P06276 4/20 0.43
MAOA P21397 4/20 0.43
ACHE P22303 4/20 0.43
MAOB P27338 4/20 0.43
TTR P02766 1/20 0.43
APP P05067 1/20 0.43
PTPN1 P18031 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3178393 1.00 HDAC1 (0.64) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL20367229 0.96 HDAC1 (0.64) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3178100 0.93 HDAC1 (0.57) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3178096 0.93 HDAC1 (0.57) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3184355 0.91 HDAC1 (0.77) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3184350 0.91 HDAC1 (0.77) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3177427 0.89 HDAC1 (0.62) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL3177432 0.89 HDAC1 (0.62) HDAC1NR1H2ESR2MAPTKDM4E
SCHEMBL27766220 0.85 KDM4E (0.48) HDAC1MAPTKDM4EALDH1A1HPGD
SCHEMBL20162169 0.84 ESR2 (0.65) HDAC1NR1H2ESR2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof NORVARTIS AG 2010-01-28 US disclosed
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof NORVARTIS AG 2010-01-28 US disclosed
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof NORVARTIS AG 2010-01-28 US disclosed
EP-2120910-A2 HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF Novartis Ag (CH) 2009-11-25 EP disclosed
WO-2008076954-A2 HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2008-06-26 WO disclosed
WO-2008076954-A2 HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022514-A1 Heterocycle Compounds and Methods of Use Thereof HDAC1, HDAC3, HDAC10 HDAC1 1/4885NR1H2 327/4885ESR2 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.